paediatric-mitral-valve-repair-shows-favourable-long-term-freedom-from-reoperation
Paediatric Mitral Valve Repair Shows Favourable Long-Term Freedom From Reoperation

Paediatric Mitral Valve Repair Shows Favourable Long-Term Freedom From Reoperation

Children undergoing mitral valve repair with autologous pericardial leaflet augmentation for rheumatic heart disease demonstrated encouraging long-term freedom from reoperation over decades of follow-up. Rheumatic heart disease remains the most frequent cause of acquired heart disease among children in low- and middle-income countries, where the mitral valve is most severely affected. Surgeons prefer repairing the native valve over replacement in children to prevent prosthesis-related complications. Extending repair feasibility in tissue-deficient valves often requires leaflet augmentation using glutaraldehyde-treated autologous pericardium, though long-term outcome data in purely paediatric rheumatic cohorts remain limited.

To evaluate long-term durability, investigators examined 66 consecutive children aged 18 years and younger who underwent surgical repair between January 1997 and December 2023 at the National Heart Institute Malaysia. Every patient had rheumatic mitral valve disease and received augmentation using 0.6 percent glutaraldehyde-treated autologous pericardium. The study team assessed primary endpoints comprising overall survival, freedom from reoperation, and freedom from valve failure, which was defined as recurrent mitral regurgitation greater than moderate or any subsequent reoperation. Time-to-event outcomes were tracked using Kaplan–Meier analysis.

The patient cohort presented with a median age of 12.0 years, spanning an interquartile range from 8.8 to 14.0 years, and 51.5 percent were female. Posterior leaflet augmentation represented the most frequent surgical approach, utilized in 51.5 percent of the cohort.

Postoperative analysis identified an early mortality rate of 4.5 percent, representing three patient deaths, alongside six additional late deaths during follow-up. Kaplan–Meier estimates revealed overall survival rates of 91.5 percent at 5 years, 91.5 percent at 10 years, and 86.9 percent at 15 years. These survival metrics reflect clinical outcomes monitored across an extended observational timeframe for this reconstructive surgical technique in young rheumatic patients.

Long-term valve performance demonstrated durable freedom from repeat surgical interventions. Cumulative freedom from reoperation was 95.0 percent at 5 years, 90.1 percent at 10 years, and 87.1 percent at 15 years. Freedom from valve failure remained high across the first decade at 91.7 percent at 5 years and 89.9 percent at 10 years, before reaching 74.7 percent at 15 years. Six patients ultimately underwent mitral valve replacement during reoperation, specifically addressing progressive stenosis in four cases and recurrent regurgitation in two.

Patients were monitored over a median follow-up of 13.03 years, with an interquartile range of 6.9 to 15.1 years. Latest echocardiographic mitral regurgitation grades were available for 42 patients. Statistical regression was treated as exploratory because events were sparse throughout follow-up. The resulting exploratory hazard-ratio estimates exhibited wide confidence intervals, and the overall Firth penalized Cox proportional hazards model was not statistically significant, yielding a p-value of 0.074.

The researchers concluded that mitral valve repair utilizing glutaraldehyde-treated autologous pericardial leaflet augmentation provides encouraging long-term freedom from reoperation in selected paediatric patients with rheumatic disease. The findings support adopting a repair-first approach when technically feasible, while acknowledging the ongoing risk of recurrent regurgitation or late stenosis. Consequently, the investigators emphasized the essential importance of maintaining continuous longitudinal echocardiographic surveillance and rheumatic secondary prophylaxis throughout paediatric care.

Subject of Research: Long-term outcomes of paediatric mitral valve repair using pericardial leaflet augmentation for rheumatic heart disease

Article Title: Mitral valve repair with leaflet augmentation for rheumatic heart disease in children: outcomes through 20 years

Article References: Chen, Y. C., Sivalingam, S., Gaaffar, I., Krishna Moorthy, P. S., Yakub, A., & Dillon, J. (2026). Mitral valve repair with leaflet augmentation for rheumatic heart disease in children: outcomes through 20 years. Journal of Cardiothoracic Surgery. https://doi.org/10.1186/s13019-026-04844-w

Image Credits: AI Generated

DOI: 10.1186/s13019-026-04844-w

Keywords: rheumatic heart disease, mitral valve repair, leaflet augmentation, autologous pericardium, paediatric cardiology, cardiac surgery, National Heart Institute Malaysia, mitral regurgitation, mitral stenosis, Kaplan-Meier analysis, freedom from reoperation, valve failure, glutaraldehyde treatment, echocardiographic surveillance, rheumatic prophylaxis, posterior leaflet augmentation